Accès ouvert
2026
article
OpenAlex
Burak Tok, Lokman Koral
Amaç: Hastanemiz Tıbbi Onkoloji Servisi’ne yatan 65 yaş ve üzeri hastaların klinik özellikleri hakkın-da bilgi edinmeyi hedefliyoruz. Ayrıca, giderek yaşlanan nüfus göz önünde bulundurularak, ileriye dö-nük bakım koşullarının iyileştirilmesine, bakım merkezleri ile sağlık personeli sayısının planlanmasına katkı sağlamayı amaçlıyoruz.Yöntem: Tıbbi Onkoloji Servisi’ne …
tr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Mustafa Gürbüz, Deniz Tural, Timuçin Çil, Hacer Demir et autres
PURPOSE: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are clinically significant in patients with cancer, as chemotherapy can trigger viral reactivation, leading to liver failure, treatment interruption, or death. Despite this risk, routine viral screening in patients with solid …
tr
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Nedim Turan, Timuçin Çil, Mehmet Artaç, İlhan Hacıbekiroğlu et autres
e20501 Background: The role of biomarkers in the treatment of non-small cell lung cancer is increasing. Biomarker evaluation is performed in almost all of the diagnosed patients and treatments are applied according to this evaluation. In this study, the frequency and testing …
tr
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Barantsevich Er, Şükrü Alperen Korkmaz, Lokman Koral, Demet Güleç Öyekçin
Objective: Grief is a natural reaction to potential losses faced by women with breast cancer.To our knowledge, no study has been conducted on prolonged grief disorder (PGD) in women with breast cancer.This study investigated the sociodemographic, cancer-specific, and psychological factors affecting PGD …
us, tr
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Mustafa Değirmenci, Gülden Dınız, Dudu Solakoğlu Kahraman, Mustafa Şahbazlar et autres
Background: Trastuzumab is commonly utilized in the management of metastatic HER2-positive breast cancer. Our main goal was to examine the clinical outcomes and immune markers of patients who received trastuzumab and chemotherapy treatment. Methods: Between 1995 and 2012, a total of 98 …
tr
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Murat Araz, İsmail Beypınar, Fatih İnci, Lokman Koral et autres
IntroductionWe compared the efficacy of first-generation granisetron and second-generation palonosetron in triplet anti-emetic prophylaxis in patients with non-small cell lung cancer (NSCLC) receiving cisplatin-based high emetogenic chemotherapy (HEC).MethodsThis prospective, multicenter, non-randomized, observational study was conducted between June 2018 and December 2021. Patients …
tr
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Mehmet Artaç, Mahmut Emre Yıldırım, Ahmet Taner Sümbül, Akın Öztürk et autres
e20512 Background: Evaluation of real-world data together with data in clinical studies is very important in the evaluation of treatment algorithms. In real life, treatments are applied to the elderly, patients with poor performance and unusual groups with comorbidities. Determining these treatment …
tr
(code pays fourni par la source)
2024
article
OpenAlex
Faysal Dane, Hakan Harputluoğlu, DENİZ TURAL, AHMET BİLİCİ et autres
Accès ouvert
2024
preprint
OpenAlex
Mustafa Değirmenci, Gülden Dınız, Dudu Solakoğlu Kahraman, Mustafa Şahbazlar et autres
Abstract Purpose Trastuzumab is commonly utilized in the management of metastatic breast cancer. Our main goal was to examine the extended outcomes of patients experiencing a persistent positive response to trastuzumab treatment. Methods Between 1995 and 2012, a total of 98 patients …
tr, kh, Somalie
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Murat Yıldırım, Timuçin Çil, Mehmet Artaç, İlhan Hacıbekiroğlu et autres
The role of driver mutations and PDL-1 status in the treatment of NSCLC is increasing. Biomarker evaluation is performed in almost all of the patients and treatments are applied according to this evaluation. In this study, the frequency and testing rates of …
tr
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Ahmet Erkan Bilici, Sinan Koca, Mustafa Karaağaç, Sabin Göktaş Aydın et autres
tr
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Yakup İriağaç, Eyyüp Çavdar, Kubilay Karaboyun, Seher Yıldız Tacar et autres
ABSTRACT Introduction: Crizotinib is a tyrosine kinase inhibitor used in patients with non-small cell lung cancer, and there are uncertainties about its effect on kidney function. In this study, it was aimed to document the possible adverse effect of the drug on …
tr
(code pays fourni par la source)